S. Sloot

Most-cited papers

1. Ligand independent EphA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype

   Kim H. T. Paraiso, M. Das Thakur, B. Fang, J. Koomen +16 more

   2014Cancer Discovery101 citations Open access

   Semantic Scholar

   Save

2. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies

   S. Sloot, Y. Chen, Xiu-Hua Zhao, Jamie L. Weber +8 more

   2017Cancer92 citations Open access

   Semantic Scholar

   Save

3. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases

   K. Ahmed, J. Freilich, S. Sloot, N. Figura +7 more

   2015Journal of Neuro-Oncology69 citations

   Semantic Scholar

   Save

4. Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study

   S. Sloot, J. Boland, J. Snowden, Yousef Ezaydi +8 more

   2014Supportive Care in Cancer43 citations Open access

   Semantic Scholar

   Save

5. Developments in Intralesional Therapy for Metastatic Melanoma

   S. Sloot, O. Rashid, A. Sarnaik, J. Zager

   2016Cancer Control: Journal of the Moffitt Cancer Cente42 citations Open access

   Semantic Scholar

   Save

6. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy

   J. V. van Roermund, Dieuwertje E. G. Kok, M. Wildhagen, L. Kiemeney +7 more

   2009BJU International29 citations

   Semantic Scholar

   Save

7. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?

   S. Sloot, Inna V. Fedorenko, K. Smalley, G. Gibney

   2014Expert Opinion on Pharmacotherapy27 citations Open access

   Semantic Scholar

   Save

8. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy

   S. Sloot, J. Zager, R. Kudchadkar, J. Messina +9 more

   2016Melanoma research26 citations

   Semantic Scholar

   Save

9. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion

   O. Rashid, S. Sloot, J. Zager

   2014Expert Opinion on Drug Metabolism & Toxicology16 citations

   Semantic Scholar

   Save

10. Intralesional therapy for metastatic melanoma

    S. Sloot, O. Rashid, J. Zager

    2014Expert Opinion on Pharmacotherapy10 citations

    Semantic Scholar

    Save

11. Challenging the knowledge base and skillset for providing surgical consent by orthopedic and plastic surgeons in the Netherlands: an identified area of improvement in patient safety

    W. Leclercq, S. Sloot, B. Keulers, S. Houterman +4 more

    2016Patient Safety in Surgery4 citations Open access

    Semantic Scholar

    Save

12. NORMAL VALUES OF CENTRAL BLOOD FLOW IN PRETERM INFANTS AFTER THE TRANSITIONAL PERIOD

    S. Sloot, K. de Waal, J. H. van der Lee, J. Kok

    20083 citations

    Semantic Scholar

    Save

13. Abstract 1610: MAPK inhibitor resistance leads to ligand-independent Ephrin A2 receptor signaling and the formation of new melanoma metastases

    Kim H. T. Paraiso, M. Das Thakur, Jobin K. John, B. Fang +14 more

    20141 citations

    Semantic Scholar

    Save

14. [Preoperative medical record-keeping can be improved: new informed consent form assists both physicians and patients].

    W. Leclercq, S. Sloot, B. Keulers, J. Legemaate +1 more

    2014Nederlandsch tijdschrift voor geneeskunde1 citations

    Semantic Scholar

    Save

15. Developments in the treatment of advanced melanoma

    S. Sloot

    20170 citations

    Semantic Scholar

    Save